62.52 USD
+1.81
2.98%
At close Apr 11, 4:00 PM EDT
After hours
62.70
+0.18
0.29%
1 day
2.98%
5 days
6.60%
1 month
0.02%
3 months
34.71%
6 months
-3.59%
Year to date
25.22%
1 year
4.67%
5 years
26.56%
10 years
-49.88%
0
Funds holding %
of 7,407 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

154% more call options, than puts

Call options by funds: $682M | Put options by funds: $268M

0.28% more ownership

Funds ownership: 5.83% [Q3] → 6.11% (+0.28%) [Q4]

7% less funds holding

Funds holding: 513 [Q3] → 476 (-37) [Q4]

21% less capital invested

Capital invested by funds: $6.93B [Q3] → $5.5B (-$1.43B) [Q4]

28% less first-time investments, than exits

New positions opened: 63 | Existing positions closed: 88

31% less repeat investments, than reductions

Existing positions increased: 137 | Existing positions reduced: 199

50% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for BUD.

Financial journalist opinion

Based on 5 articles about BUD published over the past 30 days

Positive
Zacks Investment Research
1 week ago
AB InBev Stock Progresses Well on Premiumization & Expansion Strategy
BUD's premiumization strategy looks good. It is gaining from robust consumer demand for its megabrands.
AB InBev Stock Progresses Well on Premiumization & Expansion Strategy
Positive
Zacks Investment Research
2 weeks ago
Why Anheuser-Busch Inbev (BUD) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Anheuser-Busch Inbev (BUD) is a Top Value Stock for the Long-Term
Neutral
Zacks Investment Research
2 weeks ago
The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research
Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research are included in this Analyst Blog.
The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research
Positive
Zacks Investment Research
3 weeks ago
AB InBev Shares Up 26.2% in Past 3 Months: Should You Hold or Sell?
BUD's premiumization strategy looks good. It is gaining from robust consumer demand for its megabrands.
AB InBev Shares Up 26.2% in Past 3 Months: Should You Hold or Sell?
Neutral
CNBC
4 weeks ago
Trump's 200% tariffs could have an unlikely winner — troubled beer brewers
U.S. President Donald Trump's threat to impose 200% tariffs on alcohol from Europe would serve a major blow to drinks makers on the continent. Such a levy, if enacted, could "literally wipe out" all global profits for some European drinks producers, Bernstein analyst Trevor Stirling told CNBC Friday.
Trump's 200% tariffs could have an unlikely winner — troubled beer brewers
Negative
Benzinga
1 month ago
Top 3 Risk Off Stocks That May Plunge In Q1
As of March 7, 2025, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Risk Off Stocks That May Plunge In Q1
Neutral
PRNewsWire
1 month ago
Anheuser-Busch Invests $4.2M in its Williamsburg, VA Brewery to Drive Local Economic Growth  
Leading American Manufacturer and Brewer Continues Ongoing Investments in its Communities, Buildingon $2 Billion Spend Over Last 5 Years WILLIAMSBURG, Va. , March 5, 2025 /PRNewswire/ -- Anheuser-Busch (NYSE: BUD), a leading American manufacturer and maker of Michelob ULTRA, Busch Light, Budweiser, Bud Light, and Stella Artois, today announced a new $4.2 million investment in its Williamsburg brewery.
Anheuser-Busch Invests $4.2M in its Williamsburg, VA Brewery to Drive Local Economic Growth  
Positive
Seeking Alpha
1 month ago
Anheuser-Busch InBev's Reversal Is Here: Double Digits Upside Potential Ahead
BUD's performance metrics are showing great improvements from its 5Y and 10Y averages, underscoring why the oversold status has been unwarranted. This is on top of the robust Beyond Beer and no-alcohol beer performance, along with the expanding profit margins, healthier balance sheet, and raised dividend payouts. Given the renewed growth opportunity ahead, we believe that BUD remains cheap despite the recent recovery, offering interested investors with an excellent double-digit upside potential.
Anheuser-Busch InBev's Reversal Is Here: Double Digits Upside Potential Ahead
Positive
MarketBeat
1 month ago
Anheuser-Busch Stock Rallies—Is the King of Beers Back?
Anheuser-Busch InBev NYSE: BUD stock moved sharply higher after its quarterly earnings report. The price action is building on the momentum that's been in place since the beginning of the year.
Anheuser-Busch Stock Rallies—Is the King of Beers Back?
Positive
Seeking Alpha
1 month ago
Anheuser-Busch InBev: This Beer Giant Is Pouring Profits And Brewing Value
Anheuser-Busch InBev's 2024 10-K report shows robust revenue growth and margin expansion, highlighting its strong economic moat and competitive advantages. The company's scale and premium brand mix drive significant cost advantages, making it a clear leader in the brewing industry. Improved profitability and further reduced debts could allow AB to devote a greater portion of capital to share buybacks and dividend payments.
Anheuser-Busch InBev: This Beer Giant Is Pouring Profits And Brewing Value
Charts implemented using Lightweight Charts™